$10,499.00 – $12,555.00
Imnovid has direct anti-myeloma tumoricidal activity, demonstrates an immunomodulatory effect and inhibits stromal cells that support the growth of myeloma tumor cells. Pomalidomide selectively inhibits proliferation and causes apoptosis of hematopoietic tumor cells. In addition, pomalidomide inhibits the proliferation of lenalidomide-resistant multiple myeloma cell lines and is synergistic with dexamethasone in promoting apoptosis in both lenalidomide-sensitive and lenalidomide-resistant tumor cell lines. Imnovid enhances cellular immunity with the participation of T cells and natural killer cells and inhibits the formation of proinflammatory cytokines. Pomalidomide also inhibits angiogenesis by blocking the migration and adhesion of endothelial cells.
Pomalidomide in combination with dexamethasone is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior courses of treatment, including both lenalidomide and bortezomib, and who have had disease progression on the last treatment.
Active ingredient: pomalidomide
Prescription medicine
| Дозировка | 1 Mg, 2 Mg, 3 Mg, 4 Mg |
|---|
